Patients with LUAD and exhibiting elevated levels of FSTL3 expression demonstrated a higher propensity for lymph node metastasis and presented with inferior clinicopathological staging compared to LUAD patients with lower FSTL3 expression. This evidence concerns the gene FSTL3 and metastatic malignant neoplasm in the lymph nodes.